The launch of Skintrinsiq marks the company’s entry into the complementary skincare device market
Obagi has announced the launch of Skintrinsiq device to enable physicians and other healthcare practitioners to offer enhanced skin treatments.
The device is designed to extract impurities and infuse Obagi skincare products through customised treatment protocols for individual requirements.
Obagi has developed the Skintrinsiq system with its understanding of the skin to provide a relaxing, spa-like facial experience.
The launch of Skintrinsiq marks the science-based skincare company’s entry into the complementary skincare device market.
Obagi president and CEO Jaime Castle said: “The unique design of the Skintrinsiq device combined with its exclusive availability in the physician-dispensed and spa channels allows physicians and other healthcare practitioners to provide an efficacious treatment for the skin that capitalizes on the science and heritage of Obagi products.”
Using Obagi InfuseIQ technology, Skintrinsiq helps in the extraction of impurities in the skin and absorption of Obagi products, by lifting the upper layers of the skin and opening channels.
The channels close after the Skintrinsiq vacuum stops, enabling products to lock in until the treatment is completed.
The functionality of Skintrinsiq differentiates it from other devices that depend on mechanical resurfacing to prepare the skin for application of products.
Castle said: “We know during the pandemic that skincare products for our physician customers increased in importance to their businesses, with demand from patients reaching unprecedented levels.
“Skintrinsiq’s value proposition is that the treatment has the ability to draw more patients into a practice to experience Obagi products, which will then lead to increased sales of the products.”
According to Obagi, the device helps in the meeting the growing patient demand for medical grade skincare products.
The company develops and sells advanced skin health products in more than 60 countries around the world.
In November this year, Waldencast Acquisition, a special purpose acquisition company, has signed an agreement to acquire Obagi.